Changing perceptions in pulmonary hypertension

Lancet Respir Med. 2014 Jan;2(1):21-3. doi: 10.1016/S2213-2600(13)70287-X. Epub 2013 Dec 23.

Authors

Christian Gerges¹, Irene M Lang²

Affiliations

¹ Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
² Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: irene.lang@meduniwien.ac.at.

PMID: 24461891
DOI: 10.1016/S2213-2600(13)70287-X

No abstract available

MeSH terms

Antihypertensive Agents / therapeutic use
Endothelin Receptor Antagonists / therapeutic use
Humans
Hypertension, Pulmonary / drug therapy*
Pulmonary Veno-Occlusive Disease / genetics
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Randomized Controlled Trials as Topic
Sulfonamides / therapeutic use
Thromboembolism / drug therapy
Treatment Failure
Vasodilator Agents / therapeutic use

Substances

Antihypertensive Agents
Endothelin Receptor Antagonists
Pyrazoles
Pyrimidines
Sulfonamides
Vasodilator Agents
riociguat
macitentan